Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase II

University of British Columbia

$101,240.00

Therapeutic antibody development towards granzyme B

FY 2009-10

Summary
The goal of the Proof of Principle 2 proposal is to build upon the murine antibody observations and move towards a humanized GrB therapeutic antibody. The requested $101,240 from CIHR and $202,480 from Vida Therapeutics will be used to describe the specificity, selectivity and epitope of the human GrB antibodies, and humanize the top two optimum candidates. We expect that these antibodies will make significant contributions to medical indications associated with chronic inflammation and aging, our first therapeutic indication will be the unmet need of abdominal aortic aneurysms.
Program
Proof of Principle Program - Phase II
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
195059
Name
Granville David J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
viDA Therapeutics (Northern BC)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Therapeutic antibody development towards granzyme B
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$101,240
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase II
Keyworddelim
Abdominal Aortic Aneurysm; Antibody; Granzyme B; Humanized Antibody; Therapeutic
Abstract
The goal of the Proof of Principle 2 proposal is to build upon the murine antibody observations and move towards a humanized GrB therapeutic antibody. The requested $101,240 from CIHR and $202,480 from Vida Therapeutics will be used to describe the specificity, selectivity and epitope of the human GrB antibodies, and humanize the top two optimum candidates. We expect that these antibodies will make significant contributions to medical indications associated with chronic inflammation and aging, our first therapeutic indication will be the unmet need of abdominal aortic aneurysms.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Granville, David J
Approvedterm
1 an 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $101,240~ $0~